✦ LIBER ✦

Results of two sequential chemotherapy studies in WHO Types I, III and IV lung cancer: Cyclophosphamide-5-fluorouracil (CF) and cyclophosphamide-5-fluorouracil-adriamycin (CAF)

✍ Scribed by A. Brugarolas; A.J. Lacave; A. Ribas; J.M. Buesa; M.T.Garcia Miralles

Book ID: 113146214
Publisher: Elsevier Science
Year: 1979
Weight: 360 KB
Volume: 15
Category: Article
ISSN: 0014-2964
DOI: 10.1016/0014-2964(79)90044-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination modality therapy in lung can

Combination modality therapy in lung cancer. A survival study showing beneficial results of AMCOF (adriamycin, methotrexate, cyclophosphamide, oncovin and 5-fluorouracil)

✍ Dr. Colonel Ralph D. Reynolds; Colonel Stanley O'dell 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB 👁 1 views

Thirty-seven patients with advanced or recurrent lung cancer were randomized to cytoxan (CTX) alone, COMF (CTX, oncovin, methotrexate and 5-FU) or AMCOF (adriamycin, methotrexate, CTX, oncovin and 5-FU) after receiving radiation therapy to primary and bulky tumor sites. Median survival was 3 months

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views